Core Insights - Recent surge in fund products investing in overseas markets has led to a wave of purchase limits, with nearly 90% of the 88 QDII funds linked to Nasdaq currently under purchase restrictions [1] - The strong performance of QDII funds, particularly in the context of the booming global AI industry, has resulted in rapid consumption of QDII quotas [1] - The Jiashi Global Industry Upgrade A fund has shown remarkable performance, achieving a year-to-date return of 46.15% and a two-year return of 103.68%, significantly outperforming its benchmark [1][4] Performance Metrics - Jiashi Global Industry Upgrade A fund's performance metrics include: - Year-to-date (YTD) return: 46.15% - Six-month return: 51.14% - One-year return: 48.75% - Two-year return: 103.68% [1] - The fund's net value growth rates for the past three months, six months, and one year are 29.20%, 56.34%, and 52.24% respectively, all significantly exceeding the performance benchmark [3] Investment Strategy - The fund focuses on core leading companies within the global industrial upgrade trend, with the top ten holdings accounting for 48.43% of the fund's net value [6][7] - Key holdings include major players like NVIDIA, Broadcom, and TSMC, indicating a strategic focus on technology and high-end manufacturing sectors [7] Management and Expertise - The fund is managed by experienced professionals, including Liu Jie, the Director of Large Manufacturing Research, and Chen Junjie, the main analyst for the manufacturing sector, leveraging deep research capabilities in the industrial upgrade field [8] - The fund's maximum drawdown since inception is 27.98%, indicating a higher risk profile suitable for risk-tolerant investors [8]

Core Viewpoint - The average return rate of over 300 existing QDII funds in the public market for July 2025 is 3.95%, with significant performance variations among different funds [1][3]. Group 1: Top Performing QDII Funds - The top-performing QDII funds in July 2025 are primarily related to Hong Kong pharmaceutical assets, with the Huatai-PB Hang Seng Innovation Drug ETF achieving a return of 27.74% [2][3]. - The E Fund Global Pharmaceutical Industry RMB A fund also performed well, with a return of 27.47% in July [2][6]. - Other notable funds include the GF CSI Hong Kong Innovation Drug ETF and the Huitianfu Hong Kong Advantage Selection A, both with returns of 27.04% [2][3]. Group 2: Underperforming QDII Funds - Over 40 QDII funds experienced negative returns in July 2025, particularly those focused on the Indian and Japanese markets [11]. - The Manulife India fund had the largest decline, with a return of -3.84%, while the Huaan Mitsubishi Nikkei 225 ETF linked A saw a return of -2.19% [14]. - The GF Global Healthcare A RMB fund also faced a significant drop, with a return of -1.99% [14]. Group 3: Long-term Performance - Four active equity QDII products have achieved an annualized return of over 30% since their inception, including the Jiashi Global Industrial Upgrade A and the Southern Hong Kong Digital Economy A [7][8]. - The Jiashi Global Industrial Upgrade A fund, established in February 2023, has a strong focus on major tech stocks like NVIDIA and Micron Technology [8].